Poly Medicure Ltd
Poly Medicure Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Poly Medicure aims for a sustained growth rate of 20%+ annually, seen consistently over the past 3-4 years. - Infusion therapy (70% revenue) and renal products (8-9% revenue) to drive growth with renal showing 56% growth recently. - Domestic business targeting over 20% growth, improving from a low start. - Exports grew around 28-30%; emphasis on US and Europe with expected regulatory approvals driving future gains. - Dialysis business expanding with standalone and daycare centers boosting demand; target 20-25% market share in renal by 2030. - Planned CAPEX of Rs. Poly Medicure targets a sustained revenue growth of around 20%+ annually over the next 3-5 years, building on the recent 20%-plus growth trajectory. - EBITDA margins are expected to improve by approximately 50-100 basis points per year, driven by operational efficiencies and scale benefits. - Introduction of higher-margin businesses like oncology and critical care is anticipated to contribute positively to margin expansion. - The company has recently added 60+ sales and marketing personnel in new verticals, expecting ramp-up over 2-3 years to enhance revenue. - CAPEX cycle includes ongoing and planned investments (~Rs.
From Poly Medicure Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Poly Medicure aims for a sustained growth rate of 20%+ annually, seen consistently over the past 3-4 years.
- Infusion therapy (70% revenue) and renal products (8-9% revenue) to drive growth with renal showing 56% growth recently.
- Domestic business targeting over 20% growth, improving from a low start.
- Exports grew around 28-30%; emphasis on US and Europe with expected regulatory approvals driving future gains.
- Dialysis business expanding with standalone and daycare centers boosting demand; target 20-25% market share in renal by 2030.
- Planned CAPEX of Rs. 400-500 crores over 18-20 months for new plants to support capacity expansion.
2 more points from Poly Medicure Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Poly Medicure Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Current CAPEX: Rs. 222 crores invested in 9 months FY25; plan for Rs. 300 crores total this year.
- This CAPEX primarily for existing plants, funded through internal accruals, not QIP proceeds.
- Future CAPEX: Rs. 400-500 crores planned over next 18-20 months for three new plants under construction in Palwal, Haryana.
- These new plants expected to be commissioned by mid-2026.
- All QIP proceeds (Rs. 500 crores) will be utilized for new CAPEX related to these new plants.
- Strategic investments include a JV with AMPIN for 9.9 MW solar power to run manufacturing on green energy by late 2024/early 2025.
2 more points from Poly Medicure Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Equipment & Supplies
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Poly Medicure Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Poly Medicure Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Poly Medicure Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹535 Cr, net profit ₹65 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Poly Medicure Ltd's management said in earlier quarters
Arthneeti Pro · Annual
Poly Medicure Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Poly Medicure Ltd Q3 FY25 results?
Poly Medicure aims for a sustained growth rate of 20%+ annually, seen consistently over the past 3-4 years. - Infusion therapy (70% revenue) and renal products (8-9% revenue) to drive growth with renal showing 56% growth recently. - Domestic business targeting over 20% growth, improving from a low start. - Exports grew around 28-30%; emphasis on US and Europe with expected regulatory approvals driving future gains. - Dialysis business expanding with standalone and daycare centers boosting demand; target 20-25% market share in renal by 2030. - Planned CAPEX of Rs. Poly Medicure targets a sustained revenue growth of around 20%+ annually over the next 3-5 years, building on the recent 20%-plus growth trajectory. - EBITDA margins are expected to improve by approximately 50-100 basis points per year, driven by operational efficiencies and scale benefits. - Introduction of higher-margin businesses like oncology and critical care is anticipated to contribute positively to margin expansion. - The company has recently added 60+ sales and marketing personnel in new verticals, expecting ramp-up over 2-3 years to enhance revenue. - CAPEX cycle includes ongoing and planned investments (~Rs.
What is Poly Medicure Ltd share price analysis?
Poly Medicure Ltd currently shows a neutral. The stock trades at a P/E of 52.9 with a market cap of ₹17,317 Cr. Investors should review the full earnings analysis for detailed insights.
Is Poly Medicure Ltd planning capital expenditure?
Current CAPEX: Rs.
Keep Poly Medicure Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.